Gastroenterology Research and Practice

Gastroenterology Research and Practice / 2016 / Article

Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”

  • Amin Talebi Bezmin Abadi |
  •  Article ID 1342398 |
  •  Published 21 Jan 2016

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”

  • Davide Giuseppe Ribaldone | Giorgio Saracco | Rinaldo Pellicano |
  •  Article ID 4760378 |
  •  Published 24 Aug 2016
  • | View Article

Letter to the Editor | Open Access

Volume 2016 |Article ID 1342398 | https://doi.org/10.1155/2016/1342398

Amin Talebi Bezmin Abadi, "Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”", Gastroenterology Research and Practice, vol. 2016, Article ID 1342398, 2 pages, 2016. https://doi.org/10.1155/2016/1342398

Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”

Academic Editor: Spiros D. Ladas
Received30 Dec 2015
Accepted14 Jan 2016
Published21 Jan 2016

We read with great interest the paper by Arama et al., “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients” [1]. In this randomized prospective study, they compared the eradication rates of Helicobacter pylori infection by a 7-day and 14-day anti-HP regimen. H. pylori is an infectious disease and the goal of treatment is to cure the infection [2, 3]. This transmissible infection is significantly associated with various digestive diseases and is a main cause of mortality worldwide. Taking together, H. pylori is a chronic infectious agent; thus, an ultimate demand is to eradicate it [4]. However, some points we found may help to draw better conclusion.(1)Current reported results are not unexpected within this population. The main limitation of current study is the small sample size which may not support actual representative of this population. Accordingly, a study with larger number of H. pylori positive patients is required to draw a better conclusion.(2)The optimal duration for H. pylori eradication is still controversial. The authors concluded that two weeks of anti-H. pylori regimen is preferable than 7 days. However, they did not mention the rationale for extra side effects due to the increased duration of this therapy. So, it can be a good opportunity to rethink about optimal H. pylori treatment duration.(3)Being cost-effective is an important factor for an optimum duration of H. pylori eradication regimens. However, this item is influencing 14-day treatment.Conclusively, an optimal first-line H. pylori eradication therapy has to be discovered already. Certainly, preantibiotic susceptibility tests are inevitable approach in H. pylori therapy.

Disclaimer

The contents of this review article are the sole responsibility of the author and necessarily represent personal perspective.

Conflict of Interests

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests.

References

  1. S. S. Arama, C. Tiliscan, C. Negoita et al., “Efficacy of 7-day and 14-day triple therapy regimens for the eradication of Helicobacter pylori: a comparative study in a cohort of romanian patients,” Gastroenterology Research and Practice, vol. 2016, Article ID 5061640, 7 pages, 2016. View at: Publisher Site | Google Scholar
  2. D. Y. Graham, Y.-C. Lee, and M.-S. Wu, “Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence,” Clinical Gastroenterology and Hepatology, vol. 12, no. 2, pp. 177.e3–186.e3, 2014. View at: Publisher Site | Google Scholar
  3. A. T. Abadi, T. Taghvaei, A. Ghasemzadeh, and A. M. Mobarez, “High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran,” Saudi Journal of Gastroenterology, vol. 17, no. 6, pp. 396–399, 2011. View at: Publisher Site | Google Scholar
  4. A. T. B. Abadi, “Therapy of Helicobacter pylori: present medley and future prospective,” BioMed Research International, vol. 2014, Article ID 124607, 7 pages, 2014. View at: Publisher Site | Google Scholar

Copyright © 2016 Amin Talebi Bezmin Abadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

652 Views | 340 Downloads | 1 Citation
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.